Jonathan Corren
#157,692
Most Influential Person Now
Jonathan Corren's AcademicInfluence.com Rankings
Jonathan Correnphilosophy Degrees
Philosophy
#8969
World Rank
#12456
Historical Rank
Logic
#5979
World Rank
#7446
Historical Rank
Jonathan Correnbiology Degrees
Biology
#12245
World Rank
#15709
Historical Rank
Immunology
#815
World Rank
#838
Historical Rank
Download Badge
Philosophy Biology
Jonathan Corren's Degrees
- Doctorate Medicine Stanford University
Why Is Jonathan Corren Influential?
(Suggest an Edit or Addition)Jonathan Corren's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Lebrikizumab treatment in adults with asthma. (2011) (1180)
- Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. (2001) (1140)
- Dupilumab Efficacy and Safety in Moderate‐to‐Severe Uncontrolled Asthma (2018) (1009)
- Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial (2016) (713)
- Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. (2001) (432)
- Tezepelumab in Adults with Uncontrolled Asthma (2017) (393)
- Allergic rhinitis and asthma: how important is the link? (1997) (334)
- Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies (2015) (331)
- Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma: Effects Across a Broad Range of Eosinophil Counts. (2016) (316)
- A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma. (2010) (301)
- Nasal beclomethasone prevents the seasonal increase in bronchial responsiveness in patients with allergic rhinitis and asthma. (1992) (281)
- Changes in bronchial responsiveness following nasal provocation with allergen. (1992) (277)
- Safety and tolerability of omalizumab (2009) (231)
- Conjunctivitis in dupilumab clinical trials (2019) (220)
- Rhinitis therapy and the prevention of hospital care for asthma: a case-control study. (2004) (217)
- Tezepelumab in Adults with Uncontrolled Asthma. (2019) (207)
- Incidence and characteristics of angioedema associated with enalapril. (2005) (205)
- Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma. (2021) (204)
- Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma. (2003) (190)
- Efficacy and safety of omalizumab in nasal polyposis: two randomized phase III trials. (2020) (188)
- Omalizumab is effective in the long-term control of severe allergic asthma. (2003) (184)
- Review of alleged reaction to monosodium glutamate and outcome of a multicenter double-blind placebo-controlled study. (2000) (175)
- Efficacy and safety of loratadine plus pseudoephedrine in patients with seasonal allergic rhinitis and mild asthma. (1997) (169)
- Role of Interleukin-13 in Asthma (2013) (162)
- Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines ‐ recommendations on the use of biologicals in severe asthma (2020) (146)
- Intranasal corticosteroids for allergic rhinitis: how do different agents compare? (1999) (121)
- Beta2-receptor polymorphisms in patients receiving salmeterol with or without fluticasone propionate. (2010) (120)
- The impact of allergic rhinitis on bronchial asthma. (1998) (116)
- Dupilumab Efficacy in Patients With Uncontrolled, Moderate-to-Severe Allergic Asthma. (2020) (104)
- Inhibition of interleukin-5 for the treatment of eosinophilic diseases. (2012) (97)
- Asthma phenotypes and endotypes: an evolving paradigm for classification. (2013) (97)
- COVID-19, asthma, and biological therapies: What we need to know (2020) (95)
- EAACI Biologicals Guidelines—Recommendations for severe asthma (2020) (94)
- TSLP: from allergy to cancer (2019) (88)
- Comparison of the bronchodilatory effects of cetirizine, albuterol, and both together versus placebo in patients with mild-to-moderate asthma. (1995) (86)
- Effectiveness of azelastine nasal spray compared with oral cetirizine in patients with seasonal allergic rhinitis. (2005) (84)
- Efficacy of azelastine nasal spray in seasonal allergic rhinitis patients who remain symptomatic after treatment with fexofenadine. (2004) (80)
- Multicenter, double-blind, placebo-controlled, multiple-challenge evaluation of reported reactions to monosodium glutamate. (2000) (74)
- Allergen skin tests and free IgE levels during reduction and cessation of omalizumab therapy. (2008) (70)
- The connection between allergic rhinitis and bronchial asthma (2007) (69)
- Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials (2020) (64)
- Salmeterol improves quality of life in patients with asthma requiring inhaled corticosteroids. Salmeterol Quality of Life Study Group. (1998) (63)
- Twelve-week, randomized, placebo-controlled, multicenter study of the efficacy and tolerability of budesonide and formoterol in one metered-dose inhaler compared with budesonide alone and formoterol alone in adolescents and adults with asthma. (2007) (63)
- Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines ‐ recommendations on the use of biologicals in severe asthma (2020) (62)
- Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines—Recommendations on the use of biologicals in severe asthma (2020) (59)
- Manual of Allergy and Immunology (1998) (57)
- The relationship of rhinitis and asthma, sinusitis, food allergy, and eczema. (2011) (55)
- Criteria to screen for chronic sinonasal disease. (2009) (54)
- Small airways response to naturalistic cat allergen exposure in subjects with asthma. (2006) (53)
- Anti-interleukin-5 antibody therapy in asthma and allerges (2011) (52)
- New Targeted Therapies for Uncontrolled Asthma. (2019) (50)
- Efficacy and safety of fluticasone/formoterol combination therapy in patients with moderate-to-severe asthma. (2013) (49)
- Dupilumab improves symptoms, quality of life, and productivity in uncontrolled persistent asthma. (2019) (47)
- Effective control of asthma with hydrofluoroalkane flunisolide delivered as an extrafine aerosol in asthma patients. (2001) (47)
- Pneumococcal seroconversion after vaccination for children with atopic dermatitis treated with tacrolimus ointment. (2005) (44)
- COMPARISON OF ONCE‐DAILY MOMETASONE FUROATE VERSUS ONCE‐DAILY BUDESONIDE IN PATIENTS WITH MODERATE PERSISTENT ASTHMA (2003) (42)
- Cytokine inhibition in severe asthma: current knowledge and future directions (2011) (42)
- Efficacy and safety of omalizumab in children and adolescents with moderate-to-severe asthma: A systematic literature review. (2017) (39)
- Safety of omalizumab in asthma (2011) (39)
- A 300°IR sublingual tablet is an effective, safe treatment for house-dust-mite-induced allergic rhinitis: an international, double-blind, placebo-controlled, randomized Phase III clinical trial. (2020) (37)
- Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study. (2021) (37)
- Protective effect of montelukast on lower and upper respiratory tract responses to short-term cat allergen exposure. (2004) (37)
- Clinical and biochemical effects of a combination botanical product (ClearGuard™) for allergy: a pilot randomized double-blind placebo-controlled trial (2008) (36)
- Twelve-week efficacy and safety study of mometasone furoate/formoterol 200/10 microg and 400/10 microg combination treatments in patients with persistent asthma previously receiving high-dose inhaled corticosteroids. (2010) (36)
- Dupilumab Efficacy in Uncontrolled, Moderate-to-Severe Asthma With Self-reported Chronic Rhinosinusitis. (2020) (35)
- Efficacy and safety of azelastine nasal spray at a dose of 1 spray per nostril twice daily. (2007) (35)
- The effectiveness of once-daily dosing of inhaled flunisolide in maintaining asthma control. (1997) (34)
- Allergic rhinitis: treating the adult. (2000) (33)
- Vocal cord dysfunction mimicking bronchial asthma. (1992) (32)
- Effects of omalizumab, a humanized monoclonal anti-IgE antibody, on nasal reactivity to allergen and local IgE synthesis. (2004) (32)
- Small airways disease in asthma (2008) (32)
- Optimum Treatment of Rhinitis in the Elderly (1995) (32)
- Corticosteroid tapering with benralizumab treatment for eosinophilic asthma: PONENTE Trial (2019) (31)
- Effects of omalizumab on changes in pulmonary function induced by controlled cat room challenge. (2011) (31)
- Hydrofluoroalkane Formulations of Inhaled Corticosteroids for the Treatment of Asthma (2004) (31)
- Review of azelastine nasal spray in the treatment of allergic and non-allergic rhinitis (2007) (28)
- Ureaplasma urealyticum chronic osteomyelitis in a patient with hypogammaglobulinemia. (1991) (28)
- The relationship between allergic rhinitis and bronchial asthma. (1999) (27)
- Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma (2020) (26)
- Asthma Yardstick: Practical recommendations for a sustained step-up in asthma therapy for poorly controlled asthma. (2017) (25)
- Efficacy of once-daily desloratadine/pseudoephedrine for relief of nasal congestion. (2002) (24)
- INTERRELATIONSHIP BETWEEN SINUSITIS AND ASTHMA (1994) (24)
- Dupilumab improves clinical outcomes in patients with asthma and perennial allergic rhinitis. (2020) (24)
- Tezepelumab improves patient-reported outcomes in patients with severe, uncontrolled asthma in PATHWAY. (2020) (23)
- Effects of zafirlukast upon clinical, physiologic, and inflammatory responses to natural cat allergen exposure. (2001) (23)
- Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma with and without Nasal Polyposis: A Post Hoc Analysis of the Phase 2b PATHWAY Study (2021) (22)
- Baseline type 2 biomarker levels and response to tezepelumab in severe asthma (2021) (22)
- Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma (2021) (22)
- Mometasone furoate in the management of asthma: a review (2008) (20)
- Evaluation of efficacy and safety of flunisolide hydrofluoroalkane for the treatment of asthma. (2003) (20)
- Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study. (2021) (19)
- Onset and duration of action of levocabastine nasal spray in atopic patients under nasal challenge conditions. (1999) (18)
- A randomized phase 3 study of reslizumab efficacy in relation to blood eosinophil levels in patients with moderate to severe asthma (2014) (18)
- Efficacy and Safety of Lebrikizumab in Severe Uncontrolled Asthma: Results from the Lute and Verse Phase II Randomized, Double-Blind, Placebo-Controlled Trials (2014) (18)
- Dupilumab is effective in type 2‐high asthma patients receiving high‐dose inhaled corticosteroids at baseline (2020) (17)
- Omalizumab in the treatment of asthma (2011) (16)
- Tezepelumab Treatment Effect on Annualized Rate of Exacerbations by Baseline Biomarkers in Uncontrolled Severe Asthma Patients: Phase 2b PATHWAY Study (2019) (16)
- Upper and lower respiratory disease (2003) (16)
- Omalizumab is well tolerated in adolescent/adult patients (≥12 Years) with moderate-to-severe persistent asthma (2005) (15)
- Dupilumab Improves Asthma and Sinonasal Outcomes in Adults with Moderate-to-Severe Atopic Dermatitis. (2021) (15)
- Tezepelumab Reduces Exacerbations Across All Seasons in Patients with Severe, Uncontrolled Asthma: A Post Hoc Analysis of the PATHWAY Phase 2b Study (2021) (15)
- Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma and Perennial Allergy. (2021) (15)
- Budesonide/formoterol in the treatment of asthma (2008) (14)
- Long-term safety of Mometasone Furoate administered via a dry powder inhaler in children: Results of an open-label study comparing Mometasone Furoate with Beclomethasone Dipropionate in children with persistent asthma (2009) (14)
- A cumulative dose study of levalbuterol and racemic albuterol administered by hydrofluoroalkane-134a metered-dose inhaler in asthmatic subjects. (2008) (14)
- Daclizumab improves asthma control in patients with refractory asthma (2005) (13)
- Variability in Blood Eosinophil Counts in Patients with Eosinophilic Asthma. (2020) (13)
- Lebrikizumab, An Anti-IL-13 Monoclonal Antibody, Reduces Severe Asthma Exacerbations Over 32 Weeks In Adults With Inadequately Controlled Asthma (2012) (13)
- Anti-interleukin-13 antibody therapy for asthma: one step closer (2013) (12)
- Dupilumab Efficacy in Patients Stratified by Baseline Treatment Intensity and Lung Function (2020) (12)
- Dupilumab improves asthma outcomes irrespective of frequency of previous asthma exacerbation history. (2019) (12)
- Relationship between nonallergic upper airway disease and asthma. (2007) (12)
- 251 Phase I study of anti-IgE recombinant humanized monoclonal antibody rhuMAB-E25 (E25) in adults with moderate to severe asthma (1996) (11)
- The association between allergic rhinitis and asthma in children and adolescents: epidemiologic considerations. (2000) (10)
- Clinical utility and development of the fluticasone/formoterol combination formulation (Flutiform®) for the treatment of asthma (2014) (10)
- Short-Term Subcutaneous Allergy Immunotherapy and Dupilumab are Well Tolerated in Allergic Rhinitis: A Randomized Trial (2021) (10)
- A Comprehensive Analysis of the Stability of Blood Eosinophil Levels (2021) (10)
- Use of mometasone furoate administered via a dry powder inhaler in the treatment of asthma (2010) (10)
- Dupilumab improves asthma-related patient reported outcomes in asthma patients with chronic rhinosinusitis or nasal polyposis (CRS/NP) in LIBERTY ASTHMA QUEST (2018) (9)
- Anaphylaxis. A preventable emergency. (1990) (9)
- Arg16Gly Polymorphism of the β2-adrenergic Receptor Gene Does Not Modulate Clinical Response to Salmeterol in Subjects with Asthma (2008) (9)
- Addition of ibuprofen to pseudoephedrine and chlorpheniramine in the treatment of seasonal allergic rhinitis. (2004) (9)
- Acute interstitial pneumonia in a patient with Behçet's syndrome and common variable immunodeficiency. (1990) (9)
- Real-world Clinical Characteristics, Treatment Patterns, and Exacerbations in US Patients With Asthma Newly Treated With Omalizumab. (2018) (9)
- THE LINK BETWEEN ALLERGIC RHINITIS AND ASTHMA, OTITIS MEDIA, SINUSITIS, AND NASAL POLYPS (2000) (8)
- Proceedings of the Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting 2019 (2020) (8)
- How Important Is Adherence to Inhaled Medications Before Starting a Biologic Therapy for Asthma? (2018) (8)
- The impact of tezepelumab on hospitalization and emergency department visits in patients with severe asthma. (2020) (8)
- Characterization of Chronic Rhinitis in Children (2007) (8)
- Exacerbation-Prone Asthma: A Biologic Phenotype or a Social Construct. (2021) (8)
- Long-Term Safety of Flunisolide Hydrofluoroalkane Metered-Dose Inhaler in Adults and Adolescents with Asthma (2001) (7)
- D450 OMALIZUMAB EFFICACY AND SAFETY IN NASAL POLYPOSIS: RESULTS FROM TWO PARALLEL, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIALS (2019) (7)
- Conjunctivitis in dupilumab clinical trials (2019) (7)
- Omalizumab significantly improves quality of life in patients with severe persistent asthma (2005) (7)
- Nasal response to natural cat allergen exposure is significantly greater in patients with rhinitis and asthma than in patients with rhinitis alone. (2005) (7)
- Efficacy and Safety of Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma: Results from the Phase 3 NAVIGATOR Study (2021) (7)
- D201 DUPILUMAB EFFICACY IN PATIENTS WITH UNCONTROLLED, MODERATE-TO-SEVERE ASTHMA AND SEROLOGIC EVIDENCE OF ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS (2019) (6)
- Targeting TSLP in Asthma (2022) (6)
- Biomarkers of Type 2 Airway Inflammation in Airway Disease: And Then There Were Two. (2020) (6)
- Allergic Rhinitis and Conjunctivitis (2022) (6)
- 42 – Allergic and Nonallergic Rhinitis (2014) (6)
- Effects of Combined Treatment with Cat Allergen Immunotherapy and Tezepelumab on Nasal Allergen Challenge (2020) (6)
- Patient-reported outcomes in moderate-to-severe allergic asthmatics treated with omalizumab: a systematic literature review of randomized controlled trials (2018) (6)
- Dupilumab Suppresses Inflammatory Biomarkers in Asthma Patients With or Without Allergic Rhinitis: Post Hoc Analysis of the LIBERTY ASTHMA QUEST Study: 294 (2019) (6)
- Choosing a Biologic For Patients With Severe Asthma (2021) (6)
- Glutamate Safety in the Food Supply Review of Alleged Reaction to Monosodium Glutamate and Outcome of a Multicenter Double-Blind Placebo-Controlled Study 1 , 2 (2000) (6)
- Tezepelumab demonstrates clinically meaningful improvements in asthma control (ACQ-6) in patients with uncontrolled asthma: results from a phase 2b clinical trial (2018) (6)
- D202 CONTINUED SAFETY/EFFICACY OF OMALIZUMAB IN CHRONIC RHINOSINUSITIS WITH NASAL POLYPS: AN OPEN-LABEL EXTENSION STUDY (2020) (5)
- A Randomized, Controlled Phase 3 Study, LIBERTY ASTHMA QUEST, Evaluating the Efficacy and Safety of Dupilumab in Uncontrolled Moderate-to-Severe Asthma (2018) (5)
- Advancing the Care of Severe Asthma: Differential Diagnosis, Multidisciplinary Management, and Patient Engagement. (2019) (4)
- Inflammatory Disorders Associated with Allergy: Overview of Immunopathogenesis and Implications for Treatment. (2017) (4)
- SAFETY OF ZILEUTON CONTROLLED-RELEASE TABLETS GIVEN TWICE DAILY FOR THE TREATMENT OF ASTHMA: A PLACEBO-CONTROLLED STUDY (2006) (4)
- Effect of exacerbation history on clinical response to dupilumab in moderate-to-severe uncontrolled asthma (2021) (4)
- P44 Dupilumab reduces exacerbations and improves lung function in uncontrolled, moderate-to-severe asthma patients regardless of prior exacerbation history in the phase 3 LIBERTY ASTHMA QUEST study (2018) (4)
- Tacrolimus ointment does not alter immune responses of eczematous children (2003) (4)
- DUPILUMAB EFFICACY IN UNCONTROLLED, MODERATE-TO-SEVERE ALLERGIC ASTHMA IN THE PHASE 3 LIBERTY ASTHMA QUEST STUDY (2018) (4)
- DUPILUMAB IMPROVES ASTHMA CONTROL IN PATIENTS WITH UNCONTROLLED, MODERATE-TO-SEVERE ASTHMA, REGARDLESS OF EXACERBATION HISTORY (2018) (4)
- Allergic rhinitis and asthma : How important is the link ? : New insights into allergic rhinitis: Quality of life, associated airway diseases, and antihistamine potency (1997) (4)
- Exacerbation‐prone asthma–intrinsic to severe disease or a unique phenotype? (2014) (4)
- Dupilumab Improves Asthma Control and Asthma-Related Quality of Life in Uncontrolled Persistent Asthma Patients Across All Baseline Exacerbation Rates (2017) (4)
- Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study. (2023) (4)
- Tiotropium as Add-On Therapy to ICS+LABA in Patients With Symptomatic Severe Asthma: Spirometric Assessment Over 24 Hours (2013) (4)
- Evaluation and treatment of asthma: an overview. (2005) (4)
- The Impact of Tezepelumab on Hospitalization and Emergency Department Visits in Patients with Severe Uncontrolled Asthma: Results from the Pathway Phase 2b Trial (2019) (4)
- Dupilumab Improved Asthma Control in Patients With Uncontrolled, Moderate-to-Severe Asthma, Regardless of Exacerbations in the Previous Year (2019) (4)
- ONCE-DAILY TIOTROPIUM RESPIMAT (R) DECREASES THE RINK OF EXACERBATIONS, INDEPENDENT OF BASELINE CHARACTERISTICS, IN PATIENTS WITH SYMPTOMATIC SEVERE ASTHMA WITHOUT EVIDENCE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2014) (3)
- The rhinitis-asthma link revisited. (2005) (3)
- Omalizumab Improves Outcomes in Patients with Chronic Rhinosinusitis with Nasal Polyps Irrespective of Asthma Status (2020) (3)
- Remodeling in Allergic Rhinitis. Adding New Data to an Old Debate. (2015) (3)
- Efficacy and Safety of AMG 317, an IL-4Ra Antagonist, in Atopic Asthmatic Subjects: A Randomized, Double-blind, Placebo-controlled Study (2009) (3)
- Elimination of Oral Corticosteroids (OCS) with Benralizumab Treatment in OCS-Dependent Asthmatics Using a Rapid, Personalized Algorithm: The PONENTE Trial (2021) (3)
- Dupilumab Suppresses Type 2 Biomarkers in Asthma Patients With and Without Comorbid Chronic Rhinosinusitis With or Without Nasal Polyposis (CRS/NP): Post Hoc Analysis of LIBERTY ASTHMA QUEST: 296 (2019) (3)
- Dupilumab Consistently Improves Rhinoconjunctivitis‐Specific Health‐Related Quality of Life in Patients With Uncontrolled, Moderate‐to‐Severe Asthma and Comorbid Allergic Rhinitis: Results from the Phase 3 LIBERTY ASTHMA QUEST Study: 304 (2019) (3)
- Effects of combination treatment with tezepelumab and allergen immunotherapy on nasal responses to allergen: a randomized controlled trial. (2022) (3)
- Dupilumab reduces severe exacerbation-related costs among asthma patients: Results from a phase 2b trial (2016) (3)
- Tezepelumab efficacy in patients with severe, uncontrolled asthma and comorbid nasal polyps in NAVIGATOR (2021) (3)
- Baseline FeNO Independently Predicts the Dupilumab Response in Patients with Moderate-To-Severe Asthma. (2022) (3)
- Characterization of Asthma Exacerbations by Arg16Gly Genotype in Subjects with Asthma Receiving Salmeterol Alone or with Fluticasone Propionate (2008) (3)
- Once-Daily Tiotropium Respimat® Improves Lung Function In Patients With Severe Symptomatic Asthma Independent Of Leukotriene Modifier Use (2014) (3)
- 1015 Evaluation of efficacy and duration of action of levocabastine (LEVO) nasal spray under nasal challenge conditions (1996) (2)
- Association Between Dupilumab Effect on Nasal Polyp Score and Biomarkers of Type 2 Inflammation in Patients with Chronic Rhinosinusitis with Nasal Polyps in the Phase 3 SINUS-24 and SINUS-52 Trials (2)
- Dupilumab Improved Lung Function in Patients with Uncontrolled, Moderate-to-Severe Asthma Despite Exacerbation Events During the LIBERTY ASTHMA QUEST Study (2019) (2)
- Lack of Effect of Promoter, Coding and 3′ Polymorphisms of the β2-adrenergic Receptor (ADRB2) on the Clinical Response to Salmeterol Alone or with Fluticasone Propionate in Subjects with Asthma (2008) (2)
- Dupilumab Efficacy in Patients With Uncontrolled, Moderate-to-Severe Asthma by Immunoglobin E Levels at Baseline (2019) (2)
- Effect of Tezepelumab on Exacerbations in Patients with Severe, Uncontrolled Asthma, According to Baseline Body Mass Index: Results from the Phase 2b PATHWAY Study (2020) (2)
- Safety and Tolerability of Medium and High Doses of Mometasone Furoate/Formoterol (MF/F) Combination Treatment, Administered Via a Metered-Dose Inhaler (MDI), in Severe Asthma Patients Previously Treated with High-Dose Inhaled Corticosteroids (ICS). (2009) (2)
- Clinical and biochemical effects of a combination botanical product ( ClearGuard TM ) for allergy : a pilot randomized double-blind placebo-controlled trial (2015) (2)
- A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy of Omalizumab in Prevention of Bronchoconstriction Following Environmental Aeroallergen Exposure (2010) (2)
- EFFECT OF OMALIZUMAB ON SEASONAL EXACERBATIONS IN ADOLESCENTS AND ADULTS WITH MODERATE-TO-SEVERE ALLERGIC ASTHMA (2018) (2)
- Meeting the obligation to balance bioethics and clinical trial design in asthma. (2010) (2)
- Efficacy and safety of medium and high doses of mometasone furoate/formoterol (MF/F) combination treatment in subjects with severe persistent asthma (2010) (2)
- Treatment Of Severe Asthma With A New Mometasone Furoate And Formoterol (MF/F) Combination Administered With A Pressurized Metered-Dose Inhaler Device (2010) (2)
- Dupilumab Efficacy in Patients With Uncontrolled, Moderate-to-Severe Asthma and Serologic Evidence of Allergic Bronchopulmonary Aspergillosis (2020) (2)
- Fixed-dose desloratadine and pseudoephedrine relieves moderate/severe nasal congestion in patients with seasonal allergic rhinitis (2002) (2)
- 299 Bronchial responsiveness is increased following nasal allergen challenge (1991) (2)
- Tezepelumab Efficacy in Patients with Allergic and Non-Allergic Asthma: A Post Hoc Analysis of the PATHWAY Phase 2b Study (2021) (2)
- Dupilumab Improved Lung Function in Patients with Uncontrolled, Moderate-to-Severe Asthma (2019) (2)
- Omalizumab improves asthma-specific quality of life (QoL): An analysis of data from 1071 patients (2002) (1)
- Efficacy and Safety of Budesonide and Formoterol in Asthma (2009) (1)
- Omalizumab is effective in reducing asthma exacerbations irrespective of concomitant long-acting beta2-agonist use☆ (2004) (1)
- Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma Grouped by Baseline Blood Eosinophil Count and Fractional Exhaled Nitric Oxide Level: Results from the NAVIGATOR Phase 3 Study (1)
- Burden of Persistent Asthma in Patients Treated With Medium- to High-Dose Inhaled Corticosteroids: Baseline Data From a Phase 2 Clinical Trial of Dupilumab (2015) (1)
- P59: OMALIZUMAB TO TREAT IDIOPATHIC NON‐HISTAMINERGIC ACQUIRED ANGIOEDEMA (2018) (1)
- Omalizumab Improves Quality of Life in Patients with Chronic Rhinosinusitis with Nasal Polyps and Comorbid Asthma (2020) (1)
- LONG-TERM EFFECT OF DUPILUMAB ON LUNG FUNCTION IN PATIENTS WITH TYPE 2 ASTHMA: LIBERTY ASTHMA TRAVERSE STUDY (2021) (1)
- Reductions in Asthma Exacerbation-Related Hospitalizations and Emergency Department Visits in Patients with Severe, Uncontrolled Asthma Treated with Tezepelumab: Results from the Phase 3 NAVIGATOR Study (1)
- Chapter 57 – The Influence of Upper Airway Disease on the Lower Airway (2006) (1)
- Rapid Lung Function Improvement with Lebrikizumab in Patients with Uncontrolled Asthma (2016) (1)
- P436 Efficacy of the SQ HDM SLIT-tablet on nasal congestion symptoms: results from 2 DBPC trials (2017) (1)
- Comprar Manual Of Allergy And Immunology 5th Ed. | Jonathan Corren | 9781451120516 | Lippincott Williams & Wilkins (2012) (1)
- "Blockers" can benefit from 300IR house dust mite tablet-results of a large multicentre clinical trial in house dust mite induced allergic rhinitis patients (2019) (1)
- Stability of eosinophil classifications using common cut‐points over time: 28 (2019) (1)
- Efficacy and safety of medium and high doses of mometasone furoate/formoterol (MF/F) combination treatment in subjects with severe persistent asthma (2010) (1)
- P104 TOTAL NASAL SYMPTOM SCORE IMPROVEMENT WITH BENRALIZUMAB FOR PATIENTS WITH SEVERE, EOSINOPHILIC ASTHMA (2019) (1)
- Oral Corticosteroid Tapering During Benralizumab Treatment of Severe, Uncontrolled Eosinophilic Asthma: PONENTE Phase IIIb Clinical Trial (2019) (1)
- Sinusitis and Otitis Media (2007) (1)
- Late Breaking Abstract - Efficacy and safety of tezepelumab in adults with severe asthma: A randomized phase 2 study (2017) (1)
- Efficacy of tezepelumab in patients with evidence of severe allergic asthma: Results from the phase 3 NAVIGATOR study (2022) (1)
- P220 BASELINE EXHALED NITRIC OXIDE (FENO) AS PREDICTOR OF RESPONSE TO DUPILUMAB IN UNCONTROLLED, MODERATE-TO-SEVERE ASTHMA (2020) (1)
- Dupilumab Efficacy in Asthma Patients With FEV1 60–80% Predicted on Medium-Dose ICS: liberty asthma quest Study (2019) (1)
- Adrenal function recovery after durable oral corticosteroid sparing with benralizumab in the PONENTE study (2022) (1)
- Reply. (2020) (1)
- A real-world study of ICS use in patients with severe eosinophilic asthma treated with mepolizumab. (2021) (1)
- Effects of Omalizumab on Blood Eosinophil Numbers in Patients with Allergic Asthma: 287 (2019) (1)
- Protective effect of montelukast on both lower and upper respiratory responses to acute cat allergen exposure (2004) (1)
- Once-daily evening dosing with mometasone furoate dry-powder inhaler reduces overnight and early morning symptoms of mild to moderate asthma (2003) (1)
- Exacerbation Reduction In Patients Based Upon Baseline Eosinophil Counts and FEV1 Reversibility (2020) (1)
- Dupilumab reduced impact of severe exacerbations on lung function in patients with moderate‐to‐severe type 2 asthma (2022) (1)
- TEZEPELUMAB PRODUCES CLINICALLY MEANINGFUL RESPONSES ON PATIENT-REPORTED OUTCOME MEASURES IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA: RESULTS FROM THE PHASE 3 NAVIGATOR STUDY (2021) (1)
- Influence of Key Clinical Baseline Characteristics on Benralizumab Response for Patients with Severe, Uncontrolled Asthma and Moderate Blood Eosinophilia (2020) (1)
- Variability In Absolute Blood Eosinophil (EOS) Counts Over 52 Weeks In Patients With Inadequately Controlled Eosinophilic Asthma Receiving Placebo In Two Duplicate Clinical Trials: 297 (2019) (1)
- P230 Once-daily Tiotropium Respimat® Improves Lung Function In Patients With Severe Symptomatic Asthma Independent Of Leukotriene Modifier Use (2014) (1)
- 1005 Evaluation of safety and efficacy of dexacort™ turbinaire® (DEX) nasal spray in patients with perennial allergic rhinitis (1996) (1)
- The Influence of Upper Airway Disease on the Lower Airway (2019) (0)
- P069 EFFECT OF LEBRIKIZUMAB ON LUNG FUNCTION IN PATIENTS WITH SEVERE EOSINOPHILIC ASTHMA (2021) (0)
- Late Breaking Abstract - Adrenal function improvement after oral corticosteroid reduction in benralizumab-treated severe eosinophilic asthma: PONENTE maintenance phase (2021) (0)
- Twice Daily Mometasone Furoate/formoterol 200/10 G And 400/10 G Combination Therapy Reduces Wheezing, Difficulty Breathing, And Coughing (2011) (0)
- Efficacy and safety of tezepelumab in patients with uncontrolled disease while receiving maintenance therapy for moderate or severe asthma. (2022) (0)
- Pulmonary Function and Rescue Medication Use in Patients Receiving Omalizumab in Real World Settings: A Systematic Literature Review of Nonrandomized Studies (2015) (0)
- Incidence Of Infections In Patients With Severe, Uncontrolled Asthma Treated With Tezepelumab: A Pooled Analysis Of The Phase 2b PATHWAY And Phase 3 NAVIGATOR Studies (2023) (0)
- Exacerbations, Emergency Visits, and Hospitalizations in Patients Receiving Omalizumab in Real World Settings: A Systematic Literature Review of Nonrandomized Studies (2015) (0)
- Efficacy of Dupilumab in the Prevention of Seasonal Exacerbations in Patients With and Without Evidence of an Allergic Asthma Phenotype (2022) (0)
- Botanical Combination Product Reduces Late-Phase Response To Nasal Allergen Challenge (2007) (0)
- Twice-Daily Fluticasone Propionate (FP)/Formoterol Fumarate (FM) HFA pMDI Combination Therapy Is Safe, Efficacious and Reduces Asthma Exacerbations in Patients with Moderate to Severe Asthma. (2009) (0)
- Dupilumab Efficacy in LIBERTY ASTHMA QUEST Patients With Uncontrolled, Moderate-to-Severe Asthma By Allergen Sensitization Status (2022) (0)
- Extrapolating Evidence Based Medicine of AIT into Clinical Practice in the US. (2022) (0)
- Dupilumab Efficacy in Patients with Moderate-to-Severe Type 2 Asthma With and Without Elevated Blood Neutrophils (2021) (0)
- # 1 Long-term efficacy of dupilumab in patients with uncontrolled , moderate-to-severe asthma clustered by type 2 inflammatory asthma biomarker quadrants (0)
- Characterization of Aerosolized Fel d 1 in a Clinical Model During a One Hour Cat Allergen Challenge (CAC) (2008) (0)
- P437 Clinical relevance of the SQ HDM SLIT-tablet in moderate-to-severe house dust mite allergic rhinitis (2017) (0)
- Contributors (2006) (0)
- Table of Contents (2020) (0)
- Efficacy of Tezepelumab in Patients with Moderate-to-Severe, Uncontrolled Asthma: A Pooled Analysis of the Phase 2b PATHWAY and Phase 3 NAVIGATOR Studies (2022) (0)
- Fixed Airway Obstructed Patient Including COPD (2019) (0)
- Efficacy of Twice Daily Fluticasone Propionate and Formoterol Fumarate Combination Administered Using an HFA pMDI in Patients with Moderate to Severe Asthma (2009) (0)
- Lebrikizumab Decreases Inflammatory Biomarkers in Patients with Asthma: Data from Randomized Phase 3 Trials (LAVOLTA I and II) (2023) (0)
- Development of a natural cat allergen challenge room (CACR) model (2007) (0)
- Post-hoc Analyses of Lebrikizumab Phase 3 Trials (LAVOLTA I and II): Enhanced Efficacy in Patients With Prior Exacerbations and Elevated Baseline FENO or Blood Eosinophilia (2022) (0)
- Asthma Yardstick (2017) (0)
- Tecastemizole effectively reduces total and nasal allergic symptoms (2002) (0)
- THE EFFECT OF TEZEPELUMAB ON EXACERBATIONS IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA ACCORDING TO BASELINE INHALED CORTICOSTEROID DOSE: RESULTS FROM THE PHASE 2B PATHWAY STUDY (2020) (0)
- Management of Allergic Rhinitis in Patients with Asthma (2003) (0)
- 33748 Real-world insights into quality improvement in atopic dermatitis care (2022) (0)
- Reply. (2020) (0)
- P210 Real-world comparisons of clinical characteristics and medication utilization pre- and post-omalizumab initiation in asthma patients (2017) (0)
- EFFICACY OF TEZEPELUMAB IN PATIENTS WITH UNCONTROLLED ASTHMA DESPITE RECEIVING TREATMENT FOR MODERATE OR SEVERE DISEASE: POOLED ANALYSIS OF PATHWAY AND NAVIGATOR STUDIES (2022) (0)
- Seasonal Variability of Exacerbations in Patients with Severe, Uncontrolled Asthma and Clinical Benefits of Tezepelumab: Results from the PATHWAY Phase 2b Study (2020) (0)
- Impact of Intrinsic and Extrinsic Factors on the Variability of Blood Eosinophil Levels in Asthma (2019) (0)
- Patient-Reported Outcomes (PROs) in Patients Receiving Omalizumab (OMB): A Systematic Literature Review (2016) (0)
- P223 DUPILUMAB IMPROVED ASTHMA CONTROL ACROSS BASELINE IMMUNOGLOBULIN E LEVELS: LIBERTY ASTHMA QUEST STUDY (2019) (0)
- P211 A real-world assessment of asthma exacerbations in asthma patients newly treated with omalizumab (2017) (0)
- Safety of Mometasone Furoate Dry Powder Inhaler and Comparison with Beclomethasone Dipropionate in Children with Asthma Previously Maintained on Inhaled Corticosteroids (ICS) (2004) (0)
- Effect of Dupilumab on patient-reported breathing and rescue medication use (2020) (0)
- Dupilumab Efficacy in Uncontrolled, Moderate-to-Severe Allergic and Nonallergic Asthma in the Phase 3 LIBERTY ASTHMA QUEST Study (2019) (0)
- 49 – The Influence of Upper Airway Disease on the Lower Airway (2012) (0)
- Immunomodulation of asthma: Where do we stand? (2002) (0)
- 100 Questions & Answers About Allergies (2010) (0)
- DUPILUMAB IMPROVES LUNG FUNCTION IN PATIENTS IRRESPECTIVE OF ON-STUDY ASTHMA EXACERBATIONS (2020) (0)
- Dupilumab Efficacy in Patients with Uncontrolled Moderate-to-Severe Type 2 Asthma Regardless of Perennial Aeroallergen Sensitization (2023) (0)
- Effects of Tezepelumab on Asthma Exacerbations and Type 2 Biomarkers in Patients with Severe, Uncontrolled Asthma with and Without Nasal Polyps: Results from a Post-Hoc Analysis of the Phase 2b PATHWAY Study (2020) (0)
- Brief report: poor bioavailability of sustained-release theophylline. A case for liquid theophylline. (1991) (0)
- Contributors (2019) (0)
- COVID-19-vaccination in patients receiving allergen immunotherapy (AIT) or biologics - EAACI recommendations (2021) (0)
- Type 2 Biomarkers Define a Prevalent Phenotype in Moderate-to-Severe, Uncontrolled Asthma Patients: A Pooled Analysis from Lebrikizumab All-Comers Phase 2 Trials (2016) (0)
- Efficacy of tezepelumab in patients with low and high bronchodilator reversibility in PATHWAY (2020) (0)
- D012 TEZEPELUMAB EFFICACY BY NUMBER OF SENSITIVITIES TO PERENNIAL AEROALLERGENS IN NAVIGATOR (2021) (0)
- Dupilumab Reduced Severe Exacerbations and Improved Lung Function in Patients with Uncontrolled, Moderate-to-Severe Asthma with an Eosinophilic Phenotype Across Baseline IgE Levels: LIBERTY ASTHMA QUEST Study (2020) (0)
- Comparative Assessment of Asthma Control With Budesonide and Formoterol in One Pressurized Metered-Dose Inhaler (pMDI) Versus Budesonide and Formoterol in Individual Inhalers and Placebo (2007) (0)
- Long-Term Efficacy of Dupilumab in Patients With Asthma With an Allergic Phenotype Rolled Over From LIBERTY ASTHMA QUEST: LIBERTY ASTHMA TRAVERSE Study (2021) (0)
- Reduction in Corticosteroid Use Among Patients Receiving Omalizumab in Real World Settings: A Systematic Literature Review of Non-Randomized Studies (2016) (0)
- Once daily versus twice daily dosing in patients previously maintained on ICS (2009) (0)
- Dupilumab long-term efficacy in patients with non-OCS-dependent asthma with and without evidence of allergic asthma. (2023) (0)
- Dupilumab Provides Rapid and Sustained Exacerbation Protection in Patients with Uncontrolled, Moderate-to-Severe Type 2 Inflammatory Asthma Enrolled in the LIBERTY ASTHMA QUEST Study (2021) (0)
- Use of Biomarkers in Severe Asthma (2014) (0)
- Biologic therapies in atopic diseases: How far have we come? (2022) (0)
- A025 TEZEPELUMAB EFFICACY IN SEVERE ASTHMA BY SPECIFIC ALLERGEN SENSITIVITY: RESULTS FROM THE PATHWAY STUDY (2020) (0)
- Treating asthma in the new millennium. (2000) (0)
- Not just an anti-eosinophil drug: tezepelumab treatment for type 2 asthma and beyond (2023) (0)
- EFFECT OF DUPILUMAB ON LUNG FUNCTION PARAMETERS IN ORAL CORTICOSTEROID-DEPENDENT PATIENTS WITH ASTHMA ENROLLED IN LIBERTY ASTHMA TRAVERSE (2021) (0)
- Tezepelumab Reduces Exacerbations Across All Seasons In Patients With Severe, Uncontrolled Asthma With Seasonal Allergy: Results From The Phase 3 NAVIGATOR Study (2023) (0)
- The Effect of Tezepelumab on Exacerbations in Patients with Severe, Uncontrolled Asthma According to Baseline Serum IL-5 and IL-13 Levels: Results from the Phase 2b PATHWAY Study (2020) (0)
- Inhaled drug delivery devices (2012) (0)
- EFFECT OF TEZEPELUMAB ON ASTHMA INFLAMMATORY BIOMARKER LEVELS VARIES BY BASELINE BIOMARKER LEVELS (2022) (0)
- Baseline characteristics of phase 3 randomized controlled trials of omalizumab in chronic rhinosinusitis with nasal polyps (2019) (0)
- Patterns of ICS Reduction in Patients with Severe Asthma on Mepolizumab (2021) (0)
- Adrenal Insufficiency is Not a Barrier to OCS Elimination in the PONENTE Study (2021) (0)
- Efficacy of Tezepelumab in Severe, Uncontrolled Asthma: Pooled Analysis of PATHWAY and NAVIGATOR Studies. (2023) (0)
- 8 – Allergen-specific immunotherapy (2012) (0)
- Tecastemizole 30 mg effectively reduces the symptoms of allergic rhinitis (2002) (0)
- DUPILUMAB REDUCED EXACERBATIONS AND IMPROVED LUNG FUNCTIONS IN PATIENTS WITH MODERATE-TO-SEVERE ASTHMA AND PRIOR EXACERBATIONS: LIBERTY ASTHMA TRAVERSE STUDY (2022) (0)
- Rescue-Free and Symptom-Free Days With Mometasone Furoate Dry Powder Inhaler Used Once or Twice Daily in the Evening by Patients With Persistent Asthma (2007) (0)
- Effects Of Nasal Allergen Challenge Upon Airway Responsiveness To Exercise (2008) (0)
- P212 A real-world assessment of omalizumab treatment patterns in asthma patients newly treated with omalizumab (2017) (0)
- Dupilumab Improved Pre-Bronchodilator FEV1 in Patients with Uncontrolled, Moderate-to-Severe Allergic Asthma, Regardless of Presence of Perennial Aeroallergen-Specific IgE: LIBERTY ASTHMA QUEST Study (2020) (0)
- S138 Effect of tezepelumab on exacerbations in patients with severe, uncontrolled asthma, according to baseline body mass index: results from the Phase 2b PATHWAY study (2021) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Jonathan Corren?
Jonathan Corren is affiliated with the following schools:
